{"analyses":[{"ciLowerLimit":"13.9","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"24.7","groupIds":["OG000","OG001"],"nonInferiorityComment":"Based on Miettinen \\& Nurminen method stratified by Stage (II versus III), TPS (\\>=50% versus \\<50%), Histology (Squamous versus Non-squamous) and Region (East-Asia versus non-East Asia).","nonInferiorityType":"OTHER","pValue":"<0.00001","paramType":"Difference in Percentage","paramValue":"19.2","statisticalMethod":"Stratified Miettinen and Nurminen"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"25.7","upperLimit":"35.0","value":"30.2"},{"groupId":"OG001","lowerLimit":"8.1","upperLimit":"14.5","value":"11.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"397"},{"groupId":"OG001","value":"400"}],"units":"Participants"}],"description":"mPR rate is defined as the percentage of participants having ≤10% viable tumor cells in the resected primary tumor and all resected lymph nodes following completion of neoadjuvant therapy. The mPR rates as assessed by blinded independent pathologist are presented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Neoadjuvant: Prior to surgery, participants receive up to 4 cycles (cycle length: 3 weeks) of pembrolizumab \\[200 mg, intravenous (IV); given on cycle day 1\\] in combination with platinum doublet neoadjuvant chemotherapy (NAC), consisting of cisplatin \\[75 mg/m\\^2, IV; given on cycle day 1\\] and either Gemcitabine \\[1000 mg/m\\^2, IV; given on cycle days 1 and 8\\] or Pemetrexed \\[500 mg/m\\^2, IV; given on cycle day 1\\].\n\nAdjuvant: 4-12 weeks following surgery, participants receive 13 cycles (cycle length: 3 weeks) of pembrolizumab \\[200 mg, IV; given on cycle day 1\\].","id":"OG000","title":"NAC + Neoadjuvant/Adjuvant Pembrolizumab"},{"description":"Neoadjuvant: Prior to surgery, participants receive up to 4 cycles (cycle length: 3 weeks) of placebo \\[normal saline, IV; given on cycle day 1\\] in combination with platinum doublet NAC, consisting of cisplatin \\[75 mg/m\\^2, IV; given on cycle day 1\\] and either Gemcitabine \\[1000 mg/m\\^2, IV; given on cycle days 1 and 8\\] or Pemetrexed \\[500 mg/m\\^2, IV; given on cycle day 1\\].\n\nAdjuvant: 4-12 weeks following surgery, participants receive 13 cycles (cycle length: 3 weeks) of placebo \\[normal saline, IV; given on cycle day 1\\].","id":"OG001","title":"NAC + Neoadjuvant/Adjuvant Placebo"}],"paramType":"NUMBER","populationDescription":"The analysis population consisted of all randomized participants.","reportingStatus":"POSTED","timeFrame":"Up to approximately 8 weeks following completion of neoadjuvant treatment (up to Study Week 20)","title":"Major Pathological Response (mPR) Rate","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}